These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15050796)

  • 1. [Polymyositis induced or associated with lipid-lowering drugs: five cases].
    Fauchais AL; Iba Ba J; Maurage P; Kyndt X; Bataille D; Hachulla E; Parent D; Queyrel V; Lambert M; Michon Pasturel U; Hatron PY; Vanhille P; Devulder B
    Rev Med Interne; 2004 Apr; 25(4):294-8. PubMed ID: 15050796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.
    Borges IBP; Silva MG; Misse RG; Shinjo SK
    Rheumatol Int; 2018 Feb; 38(2):293-301. PubMed ID: 29027009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
    Forcadell-Peris MJ; de Diego-Cabanes C
    Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study.
    Sailler L; Pereira C; Bagheri A; Uro-Coste E; Roussel B; Adoue D; Fournie B; Laroche M; Zabraniecki L; Cintas P; Arlet P; Lapeyre-Mestre M; Montastruc JL
    Ann Rheum Dis; 2008 May; 67(5):614-9. PubMed ID: 17768174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins as a possible cause of inflammatory and necrotizing myopathies.
    Padala S; Thompson PD
    Atherosclerosis; 2012 May; 222(1):15-21. PubMed ID: 22154355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antisynthetase syndrome: a report of four cases and literature review].
    Frikha F; Saidi N; Snoussi M; Ben Salah R; Ben Ayed M; Daoud E; Hentati Y; Makni S; Mnif Z; Boudawara T; Masmoudi H; Bahloul Z
    Rev Pneumol Clin; 2012 Dec; 68(6):351-60. PubMed ID: 23062471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents].
    Franc S; Bruckert E; Giral P; Turpin G
    Presse Med; 1997 Dec; 26(38):1855-8. PubMed ID: 9569908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
    Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
    Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regarding the mechanism of statin-induced myopathy.
    Noël B
    Am Heart J; 2005 Feb; 149(2):E3. PubMed ID: 15846246
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
    Hernández Mijares A
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presymptomatic neuromuscular disorders disclosed following statin treatment.
    Tsivgoulis G; Spengos K; Karandreas N; Panas M; Kladi A; Manta P
    Arch Intern Med; 2006 Jul; 166(14):1519-24. PubMed ID: 16864763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide.
    Lange U; Piegsa M; Müller-Ladner U; Strunk J
    Autoimmunity; 2006 May; 39(3):261-4. PubMed ID: 16769661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations.
    Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.